Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
26.12
+0.84 (3.32%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Zenas BioPharma Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Market Capitalization | 1,403 | 342 | - | - |
| Enterprise Value | 1,113 | -44 | - | - |
| Last Close Price | 26.14 | 8.19 | - | - |
| PS Ratio | 93.54 | 68.45 | - | - |
| PB Ratio | 5.62 | 1.10 | - | - |
| P/TBV Ratio | 7.14 | 1.10 | - | - |
| Debt / Equity Ratio | 0.00 | 0.00 | 0.87 | 0.03 |
| Net Debt / Equity Ratio | -1.48 | -1.12 | -1.47 | -1.37 |
| Net Debt / EBITDA Ratio | 1.48 | 2.14 | 1.32 | 0.87 |
| Net Debt / FCF Ratio | 1.83 | 2.92 | 1.17 | 1.00 |
| Asset Turnover | 0.04 | 0.02 | 0.70 | - |
| Quick Ratio | 5.57 | 6.12 | 2.44 | 2.59 |
| Current Ratio | 5.66 | 6.21 | 2.57 | 2.64 |
| Return on Equity (ROE) | -68.33% | -93.22% | -102.89% | - |
| Return on Assets (ROA) | -33.72% | -46.76% | -23.77% | - |
| Return on Capital Employed (ROCE) | -72.60% | -52.40% | -60.40% | -154.70% |
| Earnings Yield | -13.53% | -45.87% | - | - |
| FCF Yield | -11.30% | -35.00% | - | - |
| Buyback Yield / Dilution | -1252.33% | -762.01% | -2.61% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.